Skip to main content
Log in

Initial experience with ropinirole PR (prolonged release)

  • Published:
Journal of Neurology Aims and scope Submit manuscript

Abstract

Ropinirole is a non-ergolinic dopamine agonist, which has been used for over 10 years for the treatment of Parkinson’s disease. A new formulation (PR = prolonged release) has been developed, which allows the drug to be released slowly (continuously) so that it only has to be given once daily. Switching from the previous ropinirole immediate release ( ropinirole IR) to the prolonged release (ropinirole PR) formulation at the nearest equivalent total daily dose, can take place overnight and the acceptance and tolerability are good. The advantages are once-daily dosing, faster titration with good tolerability and more stable plasma levels. The new formulation is regarded as valuable addition to the currently available medications.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Tompson DJ, Vearer D (2007) Steady-State Pharmacokinetic Properties of a 24-hour Prolonged-Release Formulation of Ropinirole: Results of Two Randomised Studies in Patients with Parkinson’s Disease. Clin Therapeutics 29(12):2654–2666

    Article  CAS  Google Scholar 

  2. Stocchi F, Giorgi L (2006) Efficacy of ropinirole 24-hour prolonged release compared with immediate release formulation in early Parkinson’s disease (PD): the EASE-PD Monotherapy study. Eur J Neurology 13(Suppl. 2):205

    Article  Google Scholar 

  3. Pahwa R, Stacy MA, Factor SA, Lyons KE, Stocchi F, Hersh BP, Elmer LW, Truong DD, Earl NL, on behalf of the EASE-PD Adjunct Study Investigators (2007) Ropinirole 24-hour prolonged release. Randomized, controlled study in advanced Parkinson disease. Neurology 68:1108–1115

    Article  PubMed  CAS  Google Scholar 

  4. Chaudhuri KR, Pal S, DiMarco A, Whately-Smith C, Bridgman K, Mathew R, Pezzela FR, Forbes A, Högl B, Trenkwalder C (2002) The Parkinson Disease Sleep Scale: a new instrument for assessing sleep and nocturnal disability in Parkinson’s disease. J Neurol Neurosurg Psychiatry 73:629–635

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Wolfgang H. Jost.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jost, W.H., Buhmann, C., Fuchs, G. et al. Initial experience with ropinirole PR (prolonged release). J Neurol 255 (Suppl 5), 60–63 (2008). https://doi.org/10.1007/s00415-008-5008-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-008-5008-z

Key words

Navigation